Start Date
December 7, 2022
Primary Completion Date
March 7, 2023
Study Completion Date
March 7, 2023
ExoFlo
Patients will be randomized to one of three infusions: (1) Normal Saline 100 mL, (2) Normal saline 90 mL and ExoFlo 10 mL, which is 7x1011 EVs, and (3) Normal saline 85 mL and ExoFlo 15 mL, which is 10.5x1011 EVs. The study intervention will only be dosed on day=1
Lead Sponsor
Direct Biologics, LLC
INDUSTRY